{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-053551","form_type":"8-K","ticker":"ORIC","cik":"0001796280","company_name":"Oric Pharmaceuticals, Inc.","filed_at":"2024-05-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.157971+00:00","generated_at":"2026-06-02T22:18:06.257247+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"ORIC Pharma reports Q1 2024 cash of $331.5M; advances ORIC-114 and ORIC-944 trials","bullets":["Cash and investments $331.5M as of March 31, 2024, expected to fund operations into late 2026.","R&D expenses $22.0M in Q1 2024 vs $19.5M in Q1 2023; G&A $7.0M vs $6.2M.","Initiated three ORIC-114 Phase 1b expansion cohorts in NSCLC with EGFR/HER2 mutations; updated data expected H1 2025.","ORIC-944 initial Phase 1b data supports best-in-class profile; proceeding to combination with AR inhibitor in metastatic prostate cancer.","Strengthened cash with $125M private placement in January 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-053551","json":"https://secwatch.observer/filing/0000950170-24-053551.json","markdown":"https://secwatch.observer/filing/0000950170-24-053551.md","text":"https://secwatch.observer/filing/0000950170-24-053551.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1796280/000095017024053551/0000950170-24-053551-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1796280/000095017024053551/oric-20240506.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T22:18:06.257247+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"151f0df175e6e90880c6d0f954b07ac8cfdae6fd","claim":"Oric Pharmaceuticals, Inc. reported financial results for for the quarter ended March 31, 2024.","evidence_excerpt":"ORIC Pharmaceuticals, Inc. issued a press release announcing its financial results for the fiscal quarter ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1796280/000095017024053551/0000950170-24-053551-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"for the quarter ended March 31, 2024"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}